The Jane McLelland Off-Label Drug Protocol

Overview

Jane McLelland is a British former chartered physiotherapist who survived stage IV cervical cancer (1994), secondary lung cancer (1999), and treatment-induced myelodysplasia (2003). After conventional treatments failed to provide long-term security, she undertook an extensive self-directed review of cancer metabolism research and assembled a combination of repurposed drugs that, together with dietary changes, caused her cancers to enter remission. She documented this approach in her 2018 book How to Starve Cancer Without Starving Yourself, which has been translated into 12 languages.

McLelland’s central insight is that cancer cells are metabolically dependent on three macronutrients — glucose, glutamine, and fatty acids — and that blocking all three simultaneously creates a synergistic starvation effect that no single drug can achieve. This multi-pathway blockade is intended to prevent the “metabolic rerouting” that occurs when only one fuel line is cut. A cancer cell deprived of glucose, for example, may upregulate glutamine or fatty acid utilization as an alternative energy source; closing all three pathways simultaneously appears to reduce this compensatory mechanism.

The conceptual framework McLelland developed is known as the “Metro Map” — a visual diagram modeled on a subway system where each tunnel represents a metabolic pathway supplying energy to cancer cells. Each station on the map corresponds to a drug or supplement that may block that pathway. The map is updated periodically (second edition 2021) and accounts for cancer metabolic plasticity, the ability of cancer cells to switch between oxidative phosphorylation (OXPHOS) and glycolysis when one pathway is suppressed. The protocol is highly personalized: McLelland teaches patients to identify which fuel pathways dominate in their specific cancer histology, then build a bespoke combination from the Metro Map. A core set of drugs appears across most cancer types, however, forming the basis of the protocol described here.

Dosage and Schedule

The McLelland protocol involves gradual titration of multiple compounds. Each drug is introduced sequentially over weeks to assess individual tolerance. The table below summarizes standard dosing as described in McLelland’s published materials and the Carter (2020) clinical reference document.

Diet plays an integral role in the McLelland approach. A low-glycemic index diet with elimination of simple carbohydrates, dairy, and processed meats is recommended alongside the drug protocol. Regular moderate exercise and intermittent fasting (where tolerable given treatment status) are also emphasized. McLelland cautions that dietary restriction alone is insufficient: “dietary restriction doesn’t result in immediate depletion of nutrient at the tumor site,” which is why pharmacological agents are required to directly block metabolic pathways at the cellular level.

Mechanism of Action

Each compound in the McLelland protocol targets a distinct node in cancer cell metabolism. The combined effect is intended to block all primary fuel pathways simultaneously, preventing the metabolic flexibility that enables cancer cell survival when any single pathway is disrupted.

Metformin

Metformin activates AMPK (AMP-activated protein kinase), which inhibits mTOR signaling and suppresses the Warburg effect — the preferential use of aerobic glycolysis by cancer cells even in the presence of oxygen. It reduces IGF-1 and insulin signaling, depriving cancer cells of a key growth stimulus, and inhibits complex I of the mitochondrial electron transport chain. A 2021 peer-reviewed review confirmed metformin’s anticancer mechanism via AMPK activation and mTOR inhibition across multiple cancer models. Critically, metformin acts synergistically with statins by simultaneously blocking both OXPHOS and glycolytic pathways.

Atorvastatin

Atorvastatin (and other lipophilic statins) inhibits HMG-CoA reductase in the mevalonate pathway, blocking cholesterol synthesis and downstream isoprenoid products — farnesyl pyrophosphate and geranylgeranyl pyrophosphate — required for cancer cell membrane synthesis and proliferation. In cancer cells specifically, atorvastatin also blocks the Glut1 glucose surface receptor, reducing glucose uptake. A 2023 review in PMC documented statin mechanisms including cell cycle arrest, apoptosis via caspase activation, and YAP inactivation. The lipophilic formulation allows tissue penetration beyond the bloodstream, which is important for solid tumors.

Doxycycline

Doxycycline inhibits mitochondrial biogenesis by targeting the prokaryotic-type 70S mitoribosome present in cancer cell mitochondria, which is required for the synthesis of OXPHOS complex proteins. This mechanism selectively targets cancer stem cells (CSCs), which are highly dependent on mitochondrial OXPHOS for energy production. A 2017 study published in Cell Cycle demonstrated that doxycycline inhibits the cancer stem cell phenotype, downregulates EMT markers (N-cadherin, vimentin), and reduces cancer stemness markers (Oct4, Sox2, Nanog, CD44). This activity against CSCs is particularly significant because cancer stem cells are widely hypothesized to be responsible for tumor regrowth and treatment resistance.

Mebendazole

Mebendazole acts as an anti-tubulin agent, disrupting microtubule polymerization and preventing mitotic spindle assembly. This causes mitotic arrest followed by apoptosis. Additionally, mebendazole inhibits VEGFR2 kinase activity (reducing tumor angiogenesis), downregulates the oncogenic drivers MYC, COX-2, and Bcl-2, and depletes ALDH1+ cancer stem cell populations. A 2019 systematic review in Cancers (Basel) documented mebendazole’s activity across multiple tumor types. Notably, mebendazole can penetrate the blood-brain barrier, making it relevant for CNS malignancies. It also impairs glucose and glutamine uptake in cancer cells, contributing to the multi-pathway fuel blockade.

Berberine

Berberine activates AMPK independently and synergistically with metformin, further inhibiting mTOR signaling, NF-kB, and COX-2. It induces apoptosis via caspase-3 cleavage and cell cycle arrest at G1 and G2-M phases. A 2015 study in PMC showed berberine’s anti-cancer mechanism through AMPK activation, mTOR inhibition, NF-kB suppression, and caspase-3 induction in colorectal cancer. Berberine also blocks fatty acid synthesis via SREBP-1/2 and ACC inhibition and targets the mevalonate/cholesterol pathway, providing coverage of the lipid fuel line that complements atorvastatin.

Dipyridamole

Dipyridamole inhibits equilibrative nucleoside transporters (ENT1/ENT2), blocking the salvage pathway that cancer cells use to import nucleosides for DNA and RNA synthesis. This nucleoside starvation is particularly cytotoxic to rapidly dividing cancer cells. Dipyridamole also potentiates the cytotoxicity of antimetabolite chemotherapy agents (such as 5-FU and gemcitabine) by 2- to 10-fold by blocking nucleoside rescue. It is particularly relevant for blood cancers and protein-consuming cancers such as leukemia and myeloma.

Important Considerations

• The protocol must be personalized: identifying the dominant metabolic pathways in a specific cancer histology is essential before building a drug combination.
• It is not a replacement for standard-of-care oncology; it is intended as an adjunct to surgery, chemotherapy, and radiation.
• Metformin must be accompanied by B-vitamin supplementation (methyl-B12, methylfolate, thiamine), as chronic metformin use may deplete these vitamins.
• Statin plus metformin synergy is a cornerstone of the approach: simultaneously blocking both OXPHOS and glycolysis appears to be more effective than targeting either alone.
• Mebendazole and its veterinary equivalent fenbendazole require co-administration with fat for adequate bioavailability; without a fatty meal, absorption may be substantially reduced.
• Berberine has significant interactions with diabetes medications; blood glucose monitoring is required when used alongside metformin or other glucose-lowering agents.
• Dipyridamole can interact with adenosine and anticoagulants; it should be avoided in patients on blood thinners without specialist guidance.
• Liver function tests should be monitored regularly, particularly given the combination of mebendazole/fenbendazole with statins.
• Community implementation data suggests that coverage of all three fuel lines simultaneously is critical — blocking only one or two may lead to metabolic rerouting and disease progression.
• The protocol is detailed in McLelland’s book but should be discussed with an integrative or functional medicine oncologist for appropriate supervision.